<DOC>
	<DOCNO>NCT00541138</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , carboplatin topotecan , work different way stop growth tumor cell , either kill cell stop dividing . Tamoxifen may help carboplatin work well make tumor cell sensitive drug . PURPOSE : This phase II trial study side effect give carboplatin topotecan together tamoxifen see well work treat patient central nervous system metastasis recurrent brain spinal cord tumor .</brief_summary>
	<brief_title>Tamoxifen , Carboplatin , Topotecan Treating Patients With CNS Metastases Recurrent Brain Spinal Cord Tumors</brief_title>
	<detailed_description>OBJECTIVES : - To evaluate systemic CNS response rate progression-free overall survival patient epithelial cancer brain metastasis treat tamoxifen citrate , topotecan hydrochloride , carboplatin . - To evaluate response rate , progression-free survival , overall survival patient recurrent primary glial tumor treat regimen . - To assess toxicity drug patient . - To evaluate pharmacokinetics topotecan hydrochloride tamoxifen citrate use pair specimen cerebrospinal fluid plasma patient . OUTLINE : Patients stratify disease type ( epithelial CNS metastasis vs recurrent glial tumor ) . Patients receive topotecan IV day 1-3 ( 72 hour ) , carboplatin IV 30 minute day 4 , oral tamoxifen twice daily day 1-7 . Treatment repeat every 28 day absence disease progression unacceptable toxicity . Patients achieve complete response ( CR ) may treat 2 additional course documentation CR . Patients undergo blood sample collection baseline periodically first dose topotecan obtain plasma pharmacokinetic ( PK ) measurement topotecan tamoxifen . Some patient may also undergo cerebrospinal fluid ( CSF ) collection ass peak CSF level topotecan tamoxifen course 1 .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Spinal Cord Neoplasms</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis 1 following : Epithelial neoplasm metastatic central nervous system Recurrent refractory prior chemotherapeutic radiotherapeutic regimen standard chemotherapy whole brain radiotherapy regimen exist Stage IV disease Recurrent glial tumor ( brain spinal cord ) Received prior whole brain radiotherapy stereotactic radiotherapy OR refuse radiotherapy Patients CNS metastases previously treat radiotherapy eligible , provided persistent progressive CNS metastasis document MRI eight week end radiotherapy Patients glial tumor must show progressive disease MRI prior radiotherapy Measurable disease brain/leptomeninges brain spinal cord baseline documentation within 4 week study entry Must ≥ 1 lesion ≥ 1 cm MRI scan Ineligible refuse participation high priority institutional protocol PATIENT CHARACTERISTICS : Karnofsky performance status 50100 % Life expectancy ≥ 2 month Creatinine ≤ 1.5 mg/dL WBC 4,000/mm³ OR ANC ≥ 2,000/mm³ Platelet count ≥ 150,000/mm³ Bilirubin ≤ 1.5 mg/dL ALT AST &lt; 2 time upper limit normal Not pregnant Negative pregnancy test Fertile patient must use effective contraception No nonmalignant concurrent illness ( e.g. , cardiovascular pulmonary ) either poorly control currently available treatment severity preclude study entry No severe infection Patients ineligible lumbar puncture allow PRIOR CONCURRENT THERAPY : See Disease Characteristics At least 3 week since prior radiotherapy , immunotherapy , chemotherapy OR recover expect side effect prior therapy No patient recover major surgery No concurrent radiotherapy Concurrent steroid anticonvulsant therapy allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>tumor metastatic brain</keyword>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult diffuse astrocytoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
	<keyword>adult pilocytic astrocytoma</keyword>
	<keyword>adult pineal gland astrocytoma</keyword>
	<keyword>adult subependymal giant cell astrocytoma</keyword>
	<keyword>adult brain stem glioma</keyword>
	<keyword>adult anaplastic ependymoma</keyword>
	<keyword>adult ependymoma</keyword>
	<keyword>adult myxopapillary ependymoma</keyword>
	<keyword>adult subependymoma</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult oligodendroglioma</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>adult mixed glioma</keyword>
</DOC>